Common Respiratory Bacterium Chlamydia pneumoniae Emerges as Potential Trigger for Alzheimer’s Pathology, New Review Suggests

A groundbreaking review published in May 2024 has reignited debate over whether Chlamydia pneumoniae (Cp), a bacterium commonly causing respiratory infections like pneumonia, contributes to Alzheimer’s disease (AD) development. Led by researchers at Cedars-Sinai Medical Center, the analysis synthesizes evidence from human brain tissues, animal models, and cell studies, proposing Cp as a possible accelerant of brain inflammation and amyloid plaque formation. While not claiming causation, the findings highlight a need for longitudinal studies to clarify this infectious link amid rising AD cases, with 7.2 million Americans aged 65 and older affected in 2025.

Key Findings from the Review

The Cedars-Sinai team, headed by Dr. Maya Koronyo-Hamaoui from the Department of Neurosurgery, examined decades of data showing Cp presence in AD brains. Postmortem studies detected Cp DNA and antigens more frequently in AD patients’ neurons, microglia, and astrocytes—key brain cells—often near hallmark amyloid-beta plaques and neurofibrillary tangles. For instance, a 2006 study found PCR-positive Cp in 20 of 27 late-onset AD brains versus just 3 of 27 controls, with viable bacteria cultured from one sample.

Animal experiments bolster these observations. Intranasal infection of BALB/c mice with Cp led to amyloid-beta deposits resembling AD plaques, alongside neuroinflammation. Cell studies revealed Cp’s intracellular persistence, switching between infectious elementary bodies and replicative reticulate bodies to evade antibiotics and immunity, potentially sustaining chronic brain signals.

How Cp Might Reach and Harm the Brain

Chlamydia pneumoniae typically infects the respiratory tract but can disseminate via blood or nasal nerves, breaching the blood-brain barrier through infected monocytes. Once inside, it triggers glial activation, releasing cytokines like IL-1beta and TNF-alpha, which promote amyloid-beta production as an antimicrobial defense—ironically fueling plaque buildup.

This chronic inflammation may exacerbate neurodegeneration, especially in those with the APOE4 gene variant, a major AD risk factor linked to higher Cp loads and impaired lipid handling that bacteria exploit. Dr. Koronyo-Hamaoui noted, “No definitive studies have been performed proving or disproving Cp’s role as a causative or accelerating agent in AD pathology and cognitive decline,” emphasizing correlative rather than causal evidence.

Expert Perspectives

Experts not involved in the review offer cautious optimism. Dr. Maya Koronyo-Hamaoui, whose work spans immune responses in brain and eye tissues, stresses infection as a “contributory factor” amid multifactorial AD etiology. In related Cedars-Sinai research published in 2026, she highlighted Cp’s detection in AD retinas, correlating with brain pathology: “The eye is a surrogate for the brain… supporting retinal imaging as a noninvasive way to identify people at risk for Alzheimer’s.”

Neurologists urge restraint. Dr. Brian J. Balin, a pioneer in Cp-AD links, has shown the bacterium’s viability in AD brains and mouse models inducing Abeta1-42 accumulation. However, others like those in a 2000 Journal of Clinical Microbiology study failed to detect Cp in 101 AD samples, concluding it’s “neither strongly nor uniquely associated” with AD. A 2020 review in Brain, Behavior, and Immunity echoed this, citing inconsistent detection due to sampling variability.Historical Context and Epidemiological Clues

The Cp-AD hypothesis dates to 1998 reports of bacterial traces in AD temporal lobes. Prevalence aligns with AD risk: Cp infects up to 50% of adults via respiratory droplets, persisting asymptomatically in many. No direct epidemiological ties exist yet, but repeated infections in aging immune systems could amplify vulnerability, akin to how herpesviruses or gum disease bacteria are scrutinized.

AD’s rise—projected to affect 12.7 million U.S. seniors by 2050—underscores urgency, as current treatments like anti-amyloid antibodies slow but don’t halt progression.

Public Health Implications

If validated, Cp’s role suggests preventive strategies: prompt respiratory infection treatment, nasal hygiene, or anti-inflammatory therapies targeting bacterial persistence. For at-risk groups (e.g., APOE4 carriers over 65), routine screening via retinal imaging or blood tests could enable early intervention, potentially delaying onset. Daily habits like handwashing, avoiding crowded spaces during flu season, and managing comorbidities (diabetes, hypertension) remain vital, as they curb infections broadly.

This doesn’t mean antibiotics for dementia prevention—risks like resistance outweigh unproven gains, per experts. Instead, it reframes AD as partly preventable via infection control, much like vaccines reduced bacterial pneumonias.

Limitations and Counterarguments

Evidence gaps persist. Detection varies wildly: some labs find Cp routinely, others never, due to postmortem delays, PCR sensitivity, or contamination. Mouse models induce plaques rapidly but lack human aging timelines or full cognitive testing. Causation remains unproven without prospective human trials tracking infections to AD onset.

Critics argue Cp opportunistically colonizes damaged brains, not vice versa—like flies on garbage. A 1999 German study found no Cp in 20 AD brains via PCR and immunohistochemistry. Genetics, lifestyle, and vascular factors dominate proven risks, per Alzheimer’s Association data.

Path Forward

Standardized, large-scale cohort studies—combining genetics, imaging, and Cp assays—are essential. Meanwhile, this review spotlights infections in neurodegeneration research, urging balanced vigilance without alarmism.

Medical Disclaimer: This article is for informational purposes only and should not be considered medical advice. Always consult with qualified healthcare professionals before making any health-related decisions or changes to your treatment plan. The information presented here is based on current research and expert opinions, which may evolve as new evidence emerges.

References

1. Subedi L, et al. Chlamydia pneumoniae in Alzheimer’s disease pathology. Frontiers in Neuroscience. 2024;18:1393293. doi:10.3389/fnins.2024.1393293frontiersin+1

2. Earth.com. Common respiratory infection may be linked to Alzheimer’s. Accessed February 2026.